The financing round was led by Lilly Asia Ventures, together with Green Pine Capital Partners, CDBI Partners and others.

Based in La Jolla and Shanghai, Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics. Singlera's main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis and more. Singlera is dedicated to the development of precision medicine, striving to help patients through early, accurate and informative diagnoses.

The funding will help Singlera expand the development and commercialization of its non-invasive genomic sequencing tests for cancer and other genetic diseases. Singlera will also use the funds to further expand its R&D operations and expedite the launch of new product lines that address tumor diagnosis and personalized treatment.

Professor Yuan Gao, Chairman of Singlera Genomics, said, 'Singlera's non-invasive genomic sequencing diagnostic technologies could significantly enhance the accuracy of tumor diagnosis and provide powerful guidance for the new treatments. This new funding is a strong vote of confidence in our technologies, scientific research and commercial operations from a group of highly respected healthcare investors. They will bring in many valuable resources to fuel Singlera's growth, and we are looking forward to using the funds and these new resources to establish Singlera as the leader in the genetic testing field.'

'We are very pleased to partner with Singlera Genomics to help the company continue to strive in the field of non-invasive genomic sequencing diagnoses,' said Fei Chen, Managing partner at Lilly Asia Ventures. 'We've been very impressed with the strength of their management team, proprietary technologies and their commitment to precision medicine. With our investment and strategic resources, we look forward to working with Singlera to achieve ultimate goal of early detection and prevention of cancer and other severe diseases.'

Singlera Genomics Inc. (http://www.singleragenomics.com)

Singlera Genomics Inc., a fast-growing company focusing on non-invasive genetic testing, was co-founded in July 2014 in San Diego, California by Professor Yuan Gao (Johns Hopkins University), Professor Kun Zhang (University of California at San Diego), Mr. Jiangli Zhang (CEO), Mr. Qiang Liu (COO), Dr. Rui Liu (CTO). The company currently has R&D centers and business operations at both La Jolla, California, and Shanghai, China. Singlera has proprietary technologies in single cell sequencing, DNA methylation and bioinformatics.

Singlera's main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and other genetic disease diagnosis, as well as customized technology and scientific research services. Singlera is dedicated to the development of precision medicine, striving to help the patients through early, accurate and informative diagnoses.

Lilly Asia Ventures (http://www.lillyasiaventures.com)

Lilly Asia Ventures, founded in 2008 and headquartered in Shanghai, is a life sciences and healthcare sector focused venture capital firm, focusing predominantly on biopharmaceutical, med tech and diagnostics investments in Asia, particularly in China. As a leading biomedical venture fund, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.

Green Pine Capital Partners (http://www.pinevc.com.cn)

Green Pine Capital Partners (GPCP) was established in 2007 in Shengzhen, China. With the vision of 'Becoming one of the most valuable investment institution', Green Pine Capital is playing active roles in funding & nurturing early to high growth-stage innovative enterprises. Green Pine Capital is ranked among the highest performing VC/PE firms in China, our core investment team have over 20 years of experience on venture capital investments.

CDBI Capital (http://www.cd-pe.com/index.asp)

CDBI Partners is a healthcare focused venture capital firm actively looking into the best growth opportunities in China. Since its establishment in 2013, CDBI has built a focused portfolio on in vitro diagnosis, third-party services, medical imaging and minimal-invasive device sectors, providing valuable resources to facilitate their growth. CDBI aims to be the best partner for Chinese healthcare industry talents to realize their entrepreneurial dreams.